VAISHALI PHARMA
|
|
BOM :      NSE : VAISHALI     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
May 08,2025 |
Price(EOD): ₹ 12.05
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 157.25 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
VAISHALI PHARMA | -2.9% | -0.8% | -26.2% |
SUN PHARMACEUTICAL INDUSTRIES | -3.4% | -0.2% | 18.1% |
DIVIS LABORATORIES | -2.3% | 3.4% | 55.5% |
CIPLA | -2.6% | -0.6% | 5.9% |
TORRENT PHARMACEUTICALS | -2.3% | -2.1% | 20.4% |
DR REDDYS LABORATORIES | -2.9% | -0.2% | -8.7% |
MANKIND PHARMA | 2.2% | 0.3% | 5% |
ZYDUS LIFESCIENCES | -1.5% | -3.2% | -11.1% |
LUPIN | -2.1% | -3.9% | 25.1% |
FUNDAMENTAL ANALYSIS OF VAISHALI PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF VAISHALI PHARMA
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
370.78
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 0.42 Cr
[Latest Qtr - Dec2024 - Standalone Results ] 4.39
P/B Calculated based on Book Value of Rs 35.81 Cr
[Latest Year - Mar2024 - Standalone Results ] 1.59
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
2174% 50% 83% |
SHARE PRICE MOMENTUM OF VAISHALI PHARMA
VAISHALI PHARMA vs SENSEX
DEBT OF VAISHALI PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.35 0.41 0.79 0.52 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF VAISHALI PHARMA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2025 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF VAISHALI PHARMA
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
34.29% -43.55% -26.7% -26.69% |
0.07% -53.73% -32.69% -31.69% |
QtrlyTrend |
-4 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
VAISHALI PHARMA related INDICES
You may also like the below Video Courses
FAQ about VAISHALI PHARMA
Is VAISHALI PHARMA good for long term investment?
As on May 08,2025, the Fundamentals of VAISHALI PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of VAISHALI PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is VAISHALI PHARMA UnderValued or OverValued?
As on May 08,2025, VAISHALI PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of VAISHALI PHARMA ?
As on May 08,2025, the Intrinsic Value of VAISHALI PHARMA is Rs. 6.58 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 0.53
Fair Value [Median EV / Sales Model] : Rs. 8.03
Fair Value [Median Price / Sales Model] : Rs. 6.58
Estimated Median Fair Value of VAISHALI PHARMA : Rs. 6.58
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.